Table 3.
Associations between study variables and OS
| Study variables | HR (95% CI) | p-value | aHR (95% CI) | p-value |
|---|---|---|---|---|
| NLR groupa | ||||
| Group I | Reference | Reference | ||
| Group II | 1.10 (0.88, 1.37) | 0.410 | 0.96 (0.77, 1.20) | 0.733 |
| Group III | 1.40 (1.14, 1.72) | 0.001 | 1.04 (0.84, 1.29) | 0.727 |
| Group IV | 1.95 (1.65, 2.31) | < 0.001 | 1.36 (1.14, 1.63) | 0.001 |
| Age, years (≥ 65 vs. 18–64) | 2.04 (1.78, 2.33) | < 0.001 | 1.64 (1.42, 1.89) | < 0.001 |
| Male sex (vs. female) | 1.20 (1.05, 1.37) | 0.009 | 1.22 (1.06, 1.40) | 0.005 |
| Chemotherapy | ||||
| IRI, OXA | 0.29 (0.25, 0.35) | < 0.001 | 0.35 (0.30, 0.43) | < 0.001 |
| 5FU, others | 0.46 (0.38, 0.55) | < 0.001 | 0.47 (0.39, 0.57) | < 0.001 |
|
Chemotherapy < 4 times/ duration < 3 months/no chemotherapy |
Reference | Reference | ||
| Comorbidity | ||||
| DM | 1.39 (1.19, 1.62) | < 0.001 | ||
| HTN | 1.35 (1.18, 1.55) | < 0.001 | ||
| CAD | 1.66 (1.28, 2.15) | < 0.001 | ||
| CVA | 1.83 (1.37, 2.45) | < 0.001 | ||
| CKD | 3.30 (2.51, 4.34) | < 0.001 | 1.94 (1.46, 2.58) | < 0.001 |
| COPD/asthma | 1.56 (1.18, 2.06) | 0.002 | ||
| Tumor location (left vs. right) | 0.76 (0.66, 0.87) | < 0.001 | ||
| T stage | ||||
| 1, 2 | Reference | Reference | ||
| 3 | 1.84 (1.32, 2.58) | < 0.001 | 1.43 (1.02, 2.01) | 0.040 |
| 4 | 3.10 (2.21, 4.34) | < 0.001 | 2.15 (1.52, 3.04) | < 0.001 |
| N stage | ||||
| 1 | Reference | Reference | ||
| 2 | 1.80 (1.58, 2.06) | < 0.001 | 1.81 (1.58, 2.08) | < 0.001 |
| Histologic grade | ||||
| Well, Moderate | Reference | Reference | ||
| Poorly, Undifferentiated | 1.50 (1.25, 1.80) | < 0.001 | 1.29 (1.07, 1.55) | 0.009 |
| Unknown | 0.80 (0.63, 1.02) | 0.078 | 0.85 (0.67, 1.09) | 0.210 |
| CEA, ng/mL | ||||
| Normal (< 5) | Reference | Reference | ||
| Elevated (≥ 5) | 1.65 (1.41, 1.92) | < 0.001 | 1.28 (1.10, 1.50) | 0.002 |
| Unknown | 1.41 (1.18, 1.68) | < 0.001 | 1.19 (0.99, 1.43) | 0.058 |
| Hemoglobin, g/dLb | ||||
| Normal | Reference | |||
| Low | 1.41 (1.22, 1.63) | < 0.001 | ||
| Albumin, g/dL | ||||
| > 3.5 | Reference | Reference | ||
| ≤ 3.5 | 2.64 (2.26, 3.08) | < 0.001 | 1.65 (1.39, 1.95) | < 0.001 |
| Unknown | 1.54 (1.17, 2.03) | 0.002 | 1.29 (0.97, 1.71) | 0.081 |
P-values < 0.05 are shown in bold
aGroup I: pre-op NLR ≤ 2.5 and post-op NLR ≤ 1.5; Group II: pre-op NLR ≤ 2.5 and post-op NLR > 1.5; Group III: pre-op NLR > 2.5 and post-op NLR ≤ 1.5; Group IV: pre-op NLR > 2.5 and post-op NLR > 1.5
bMale ≤ 13.5 g/dL, female ≤ 12 g/dL